Skip to main content Help with accessibility Skip to main navigation

Alirocumab

Indication

In Patients with established Cardiovascular Disease - under review

Grey

Brand:

Praluent

Nice TA:

Commissioning responsibility:

CCG

PbR excluded:

No

BNF chapter:
Cardiovascular system

Background

Under review

Recommendation

LSCMMG Recommendation:

Grey

Reason for decision:

Not recommended for prescribing on the NHS in Lancashire & South Cumbria

Supporting documents:

Decisions of Lancashire local decision making groups

Pending
Pending
Pending
Pending
Pending
Pending
Pending
Pending
What do the colours mean?

Last Updated: 01 - Sep - 2019